-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
correct -X- _ O
management -X- _ O
of -X- _ O
immunocompromised -X- _ O
patients -X- _ O
with -X- _ O
pneumonia -X- _ O
is -X- _ O
debated. -X- _ O
We -X- _ O
evaluated -X- _ O
the -X- _ O
prevalence -X- _ O
, -X- _ O
risk -X- _ O
factors -X- _ O
, -X- _ O
and -X- _ O
characteristics -X- _ O
of -X- _ O
immunocompromised -X- _ B-Patient
patients -X- _ I-Patient
coming -X- _ I-Patient
from -X- _ I-Patient
the -X- _ I-Patient
community -X- _ I-Patient
with -X- _ I-Patient
pneumonia. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
We -X- _ O
conducted -X- _ O
a -X- _ O
secondary -X- _ O
analysis -X- _ O
of -X- _ O
an -X- _ O
international -X- _ O
, -X- _ O
multicenter -X- _ O
study -X- _ O
enrolling -X- _ O
adult -X- _ O
patients -X- _ O
coming -X- _ O
from -X- _ O
the -X- _ O
community -X- _ O
with -X- _ O
pneumonia -X- _ O
and -X- _ O
hospitalized -X- _ O
in -X- _ O
222 -X- _ O
hospitals -X- _ O
in -X- _ O
54 -X- _ O
countries -X- _ O
worldwide. -X- _ O
Risk -X- _ O
factors -X- _ O
for -X- _ O
immunocompromise -X- _ O
included -X- _ O
AIDS -X- _ O
, -X- _ O
aplastic -X- _ O
anemia -X- _ O
, -X- _ O
asplenia -X- _ O
, -X- _ O
hematological -X- _ O
cancer -X- _ O
, -X- _ O
chemotherapy -X- _ O
, -X- _ O
neutropenia -X- _ O
, -X- _ O
biological -X- _ O
drug -X- _ O
use -X- _ O
, -X- _ O
lung -X- _ O
transplantation -X- _ O
, -X- _ O
chronic -X- _ O
steroid -X- _ O
use -X- _ O
, -X- _ O
and -X- _ O
solid -X- _ O
tumor. -X- _ O
RESULTS -X- _ O
: -X- _ O
At -X- _ B-Outcome
least -X- _ I-Outcome
1 -X- _ I-Outcome
risk -X- _ I-Outcome
factor -X- _ I-Outcome
for -X- _ I-Outcome
immunocompromise -X- _ I-Outcome
was -X- _ I-Outcome
recorded -X- _ I-Outcome
in -X- _ I-Outcome
18 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
3702 -X- _ I-Outcome
patients -X- _ I-Outcome
enrolled. -X- _ I-Outcome
The -X- _ I-Outcome
prevalences -X- _ I-Outcome
of -X- _ I-Outcome
risk -X- _ I-Outcome
factors -X- _ I-Outcome
significantly -X- _ I-Outcome
differed -X- _ I-Outcome
across -X- _ I-Outcome
continents -X- _ I-Outcome
and -X- _ I-Outcome
countries -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
chronic -X- _ I-Outcome
steroid -X- _ I-Outcome
use -X- _ I-Outcome
( -X- _ I-Outcome
45 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
hematological -X- _ I-Outcome
cancer -X- _ I-Outcome
( -X- _ I-Outcome
25 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
chemotherapy -X- _ I-Outcome
( -X- _ I-Outcome
22 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
common. -X- _ I-Outcome
Among -X- _ I-Outcome
immunocompromised -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
community-acquired -X- _ I-Outcome
pneumonia -X- _ I-Outcome
( -X- _ I-Outcome
CAP -X- _ I-Outcome
) -X- _ I-Outcome
pathogens -X- _ I-Outcome
were -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
frequently -X- _ I-Outcome
identified -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
prevalences -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
differ -X- _ I-Outcome
from -X- _ I-Outcome
those -X- _ I-Outcome
in -X- _ I-Outcome
immunocompetent -X- _ I-Outcome
patients. -X- _ I-Outcome
Risk -X- _ I-Outcome
factors -X- _ I-Outcome
for -X- _ I-Outcome
immunocompromise -X- _ I-Outcome
were -X- _ I-Outcome
independently -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
neither -X- _ I-Outcome
Pseudomonas -X- _ I-Outcome
aeruginosa -X- _ I-Outcome
nor -X- _ I-Outcome
nonâ€“community-acquired -X- _ I-Outcome
bacteria. -X- _ I-Outcome
Specific -X- _ I-Outcome
risk -X- _ I-Outcome
factors -X- _ I-Outcome
were -X- _ I-Outcome
independently -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
fungal -X- _ I-Outcome
infections -X- _ I-Outcome
( -X- _ I-Outcome
odds -X- _ I-Outcome
ratio -X- _ I-Outcome
for -X- _ I-Outcome
AIDS -X- _ I-Outcome
and -X- _ I-Outcome
hematological -X- _ I-Outcome
cancer -X- _ I-Outcome
, -X- _ I-Outcome
15.10 -X- _ I-Outcome
and -X- _ I-Outcome
4.65 -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
; -X- _ I-Outcome
both -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.001 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
mycobacterial -X- _ I-Outcome
infections -X- _ I-Outcome
( -X- _ I-Outcome
AIDS -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.006 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
viral -X- _ I-Outcome
infections -X- _ I-Outcome
other -X- _ I-Outcome
than -X- _ I-Outcome
influenza -X- _ I-Outcome
( -X- _ I-Outcome
hematological -X- _ I-Outcome
cancer -X- _ I-Outcome
, -X- _ I-Outcome
5.49 -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
.001 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
Our -X- _ O
findings -X- _ O
could -X- _ O
be -X- _ O
considered -X- _ O
by -X- _ O
clinicians -X- _ O
in -X- _ O
prescribing -X- _ O
empiric -X- _ O
antibiotic -X- _ O
therapy -X- _ O
for -X- _ O
CAP -X- _ O
in -X- _ O
immunocompromised -X- _ O
patients. -X- _ O
Patients -X- _ B-Outcome
with -X- _ I-Outcome
AIDS -X- _ I-Outcome
and -X- _ I-Outcome
hematological -X- _ I-Outcome
cancer -X- _ I-Outcome
admitted -X- _ I-Outcome
with -X- _ I-Outcome
CAP -X- _ I-Outcome
may -X- _ I-Outcome
have -X- _ I-Outcome
higher -X- _ I-Outcome
prevalences -X- _ I-Outcome
of -X- _ I-Outcome
fungi -X- _ I-Outcome
, -X- _ I-Outcome
mycobacteria -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
noninfluenza -X- _ I-Outcome
viruses -X- _ I-Outcome
. -X- _ O

